Communiqués Johnson & Johnson Buenos Aires S.E.

Actions

JNJ

ARDEUT110236

Cours en clôture Buenos Aires S.E. Autres places de cotation 00:00:00 30/05/2024			Varia. 5j.	Varia. 1 janv.
11 780 ^ARS	+0,76%		-5,93%	+16,24%

20:52	Les parlementaires américains demandent au FBI de leur fournir des informations sur les liens de GenScript Biotech avec la Chine	RE
20:05	Mise à jour sectorielle : Les actions du secteur de la santé progressent vendredi après-midi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	17:54	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	14:46	BU
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	29/05	PU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05	AQ
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	28/05	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	28/05	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	24/05	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	24/05	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	22/05	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	22/05	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	21/05	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	21/05	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	21/05	AQ
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Transcript	17/05	PU
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment	16/05	BU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Transcript	15/05	PU
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Press Release	15/05	PU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Press Release	15/05	PU
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	08/05	BU
Intravesical drug delivery system exhibits bladder cancer benefit	07/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30